This trial studies how two diabetes treatments affect heart health in people with type 2 diabetes without heart failure.
- Type 2 Diabetes
1 Primary · 7 Secondary · Reporting Duration: Outcome will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)
Awards & Highlights
2 Treatment Groups
1 of 2
1 of 2
36 Total Participants · 2 Treatment Groups
Primary Treatment: Empagliflozin 25 MG + Liraglutide 1.8 MG · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this experiment currently admitting participants?
"The information on clinicaltrials.gov confirms that this medical trial is not currently enrolling patients. Initially posted on January 24th 2019, it was last updated September 1st 2020 and no longer seeks participants; however, 2261 other studies are still actively recruiting at the moment." - Anonymous Online Contributor
To what medical conditions is Empagliflozin 25 MG + Liraglutide 1.8 MG prescribed?
"Empagliflozin 25 MG + Liraglutide 1.8MG is frequently utilized for hospitalizations, but can also be used therapeutically to combat diet-related issues, inadequate control when relying upon a single medication treatment plan, and cardiovascular diseases." - Anonymous Online Contributor
To what extent does the combination of Empagliflozin 25 MG + Liraglutide 1.8 MG pose a risk to patients?
"Due to the lack of clinical data that has been gathered on efficacy, Empagliflozin 25 MG + Liraglutide 1.8 MG was given a rating of 2 for safety based on our team's assessment at Power." - Anonymous Online Contributor
To what capacity is this investigation accommodating participants?
"At this time, recruitment for the trial is closed. The initial posting was on January 24th 2019 and the most recent update occurred in September 2020. If searching for other studies with a similar diagnosis, 2187 trials are currently recruiting patients diagnosed with type 2 diabetes, while 74 clinical trials are seeking participants to test Empagliflozin 25 MG + Liraglutide 1.8 MG as an intervention." - Anonymous Online Contributor